Review Papers Claim by Claim

Detailed critical analysis

1. Primary data and claim: The authors genotyped HLA-DMA and DMB exon 3 polymorphisms in 163 RA patients and 146 ethnically matched controls and report increased DMB*0101 allele frequency (83% vs 72.3%, P < 1.6×10^-3) and increased DMB*0101/*0101 homozygotes (70.8% vs 50%, P < 4.2×10^-4, OR=2.4, 95% CI 1.43–4), concluding that HLA-DM alleles may influence RA susceptibility (Perdriger et al. 1999 (DMB association paper)
2. Biological plausibility: HLA-DM functions as a peptide-editor for MHC-II; variation in DM could alter peptide repertoires and T-cell selection/presentation, making the hypothesis mechanistically plausible. However, HLA-DRB1 remains the dominant MHC-II genetic effect in RA and additional MHC and non-MHC loci typically require large cohorts for robust detection (Lancet RA reviewImmunity RA review)
3. Strengths:
   • Clear, standard genotyping methods for the time (PCR-SSOP, reverse dot blot) and use of multiple statistical corrections (Bonferroni) to control false positives.
   • Stratified analyses and explicit tests for linkage disequilibrium between DM and DRB1 alleles to assess independence of signal.
   • Effect size reported (OR with CI), enabling interpretation of practical magnitude.
4. Limitations & potential biases:
   • Sample size is modest by modern genetic standards (163 cases / 146 controls). This raises the risk that effect sizes are inflated (winner's curse) and that results may not replicate in independent cohorts or other ethnic groups (population stratification risk).
   • Population is geographically restricted (Brittany, France). MHC allele distributions differ across populations; the DMB*0101 baseline frequency (≈72% in their controls) is population-specific and the association may not generalize (Perdriger et al. 1999 (DMB association paper))
   • Multiple testing corrections were applied, but the DM/DRB1 pairwise matrix creates correlated tests; residual false positives can persist. Additionally, some reported P-values are near corrected thresholds.
   • No functional assay was provided to show how DMB*0101 alters peptide editing or presentation; association does not prove causation.
   • The paper pre-dates GWAS and modern imputation; dense SNP mapping of the MHC now shows many independent signals — single-locus reports need replication in larger, well-controlled datasets.
5. Replication and subsequent evidence: The paper is an early candidate-gene association (1999). Robust confirmation would require independent replication in larger cohorts or family-based tests, or evidence from GWAS fine-mapping that a DMB locus independently associates with RA after conditioning on DRB1. Modern large-scale RA GWAS emphasize DRB1 and many non-MHC loci; limited or inconsistent replication of specific HLA-DM allele effects suggests the original finding needs cautious interpretation (Lancet RA review).
6. What would disprove/change the conclusion?
   • Failure to replicate the DMB*0101 association in independent, larger cohorts or family-based designs, especially after controlling for population stratification and DRB1 haplotypes.
   • Fine-mapping that shows the signal is better explained by another linked MHC variant (e.g., non-DM coding or regulatory variant) when using dense SNP data and imputation.
   • Functional data showing DMB*0101 protein behaves identically to other alleles in peptide editing and no impact on peptide repertoires relevant to RA would weaken causality claims.
7. Recommended next steps / experiments:
   1. Attempt replication in large, well-powered case-control cohorts and family trios, including multiple European populations and non-European ancestries, with dense MHC genotyping/imputation to condition on DRB1 haplotypes.
   2. Functional assays: compare peptide-exchange/editing activity of DMB*0101 versus other DMB alleles (in vitro MHC-II peptide-loading assays, mass spectrometry of presented peptidomes in cells expressing different DMB alleles).
   3. Assess expression/regulatory differences: measure DMB mRNA/protein in antigen-presenting cells from carriers vs non-carriers to test whether allele correlates with expression or splicing differences.
8. Practical conclusion & confidence: The paper provides plausible, moderately strong early evidence that HLA-DMB*0101 correlates with RA risk in this French cohort, with an effect size (OR≈2.4) large for a single allele; however, limitations (modest sample size, population specificity, absence of functional data, and lack of large-scale replication) reduce confidence in generalizability. I rate the biological plausibility as moderate-to-strong but the epidemiologic certainty as moderate-to-low until replication and fine-mapping are performed (Immunity RA review).